01:19 , Dec 18, 2010 |  BC Extra  |  Top Story

Cephalon's Baldino passes away

Cephalon Inc. (NASDAQ:CEPH) said founder, Chairman and CEO Frank Baldino Jr. died Thursday evening. Baldino, 57, had been on medical leave since August. COO J. Kevin Buchi will continue to assume Baldino's responsibilities in the...
07:00 , Oct 25, 2010 |  BC Week In Review  |  Company News

BioAssets, Cephalon deal

Cephalon exercised its option to acquire BioAssets for $12.5 million after receiving positive interim data from a Phase II trial of BioAssets' biosimilar version of autoimmune drug Enbrel etanercept to treat sciatica. BioAssets shareholders will...
07:00 , Oct 25, 2010 |  BioCentury  |  Finance

Regulatory milestones

Regulatory milestones Amgen Inc. (NASDAQ:AMGN) gained $0.84 to $57.55 last week after an FDA advisory committee decided against recommending any label changes for anemia drug Aranesp darbepoetin alfa. The committee met after the erythropoiesis stimulating...
00:31 , Oct 22, 2010 |  BC Extra  |  Company News

Cephalon to acquire BioAssets

Cephalon Inc. (NASDAQ:CEPH) exercised its option to acquire BioAssets Development Corp. (Wellesley, Mass.) for $12.5 million after receiving interim data from a Phase II trial of BioAssets' biosimilar version of autoimmune drug Enbrel etanercept to...
08:00 , Feb 8, 2010 |  BioCentury  |  Strategy

Footprint for growth

Investors often worry that when companies add low-margin products to a high-margin portfolio, earnings will suffer. Cephalon Inc. Chairman and CEO Frank Baldino says the company's proposed acquisition of generics company Mepha AG should allow...
08:00 , Nov 2, 2009 |  BC Week In Review  |  Company News

BioAssets, Cephalon deal

Cephalon will pay $30 million for an option to acquire BioAssets. The option will be exercisable up until 60 days following the receipt of one-month patient response data from a proof-of-concept Phase II trial of...
08:00 , Nov 2, 2009 |  BioCentury  |  Finance

Ebb & Flow

Last week's low-money down acquisition of Metabasis Therapeutics Inc. (NASDAQ:MBRX) by cancer and inflammation play Ligand Pharmaceuticals Inc. (NASDAQ: LGND) is the latest example of a structured acquisition with contingent payouts over time. Ligand could...
00:28 , Oct 27, 2009 |  BC Extra  |  Company News

Cephalon gains option to acquire BioAssets

Cephalon Inc. (NASDAQ:CEPH) will pay $30 million for an option to acquire BioAssets Development Corp. (Wellesley, Mass.). The option will be exercisable up until 60 days following the receipt of one-month patient response data from...